Search research articles
Contact Us
Filters
Showing results (41-50 of 87) with videos related to
Page
of 9
Sort By:
Cancer Cell
|
March 7, 2003
BCR/ABL activates mdm2 mRNA translation via the La antigen
Rossana Trotta, Tatiana Vignudelli, Olivia Candini, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 22, 2006
Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study
Peter Paschka, Guido Marcucci, Amy S Ruppert, et al.
Cancer Research
|
June 17, 2010
Essential requirement for PP2A inhibition by the oncogenic receptor c-KIT suggests PP2A reactivation as a strategy to treat c-KIT+ cancers
Kathryn G Roberts, Amanda M Smith, Fiona McDougall, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 28, 2017
Concurrent Inhibition of Pim and FLT3 Kinases Enhances Apoptosis of FLT3-ITD Acute Myeloid Leukemia Cells through Increased Mcl-1 Proteasomal Degradation
Shivani Kapoor, Karthika Natarajan, Patrick R Baldwin, et al.
Cancer Cell
|
November 13, 2007
Rac guanosine triphosphatases represent integrating molecular therapeutic targets for BCR-ABL-induced myeloproliferative disease
Emily K Thomas, Jose A Cancelas, Hee-Don Chae, et al.
The Journal of Experimental Medicine
|
September 19, 2007
The PP2A inhibitor SET regulates natural killer cell IFN-gamma production
Rossana Trotta, David Ciarlariello, Jessica Dal Col, et al.
Science Signaling
|
August 1, 2013
miR-29 acts as a decoy in sarcomas to protect the tumor suppressor A20 mRNA from degradation by HuR
M Y Balkhi, Mumtaz Y Balkhi, O Hans Iwenofu, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
March 9, 2011
Mutated beta-catenin evades a microRNA-dependent regulatory loop
Angelo Veronese, Rosa Visone, Jessica Consiglio, et al.
Journal of Hematology & Oncology
|
March 19, 2013
Silvestrol exhibits significant in vivo and in vitro antileukemic activities and inhibits FLT3 and miR-155 expressions in acute myeloid leukemia
Houda Alachkar, Ramasamy Santhanam, Jason G Harb, et al.
Haematologica
|
May 11, 2019
Somatic variants in epigenetic modifiers can predict failure of response to imatinib but not to second-generation tyrosine kinase inhibitors
Georgios Nteliopoulos, Alexandra Bazeos, Simone Claudiani, et al.
Page
of 9
Search research articles
Search
Showing results (41-50 of 87) with videos related to
Sort By:
Page
of 9
Cancer Cell
|
March 7, 2003
BCR/ABL activates mdm2 mRNA translation via the La antigen
Rossana Trotta, Tatiana Vignudelli, Olivia Candini, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 22, 2006
Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study
Peter Paschka, Guido Marcucci, Amy S Ruppert, et al.
Cancer Research
|
June 17, 2010
Essential requirement for PP2A inhibition by the oncogenic receptor c-KIT suggests PP2A reactivation as a strategy to treat c-KIT+ cancers
Kathryn G Roberts, Amanda M Smith, Fiona McDougall, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 28, 2017
Concurrent Inhibition of Pim and FLT3 Kinases Enhances Apoptosis of FLT3-ITD Acute Myeloid Leukemia Cells through Increased Mcl-1 Proteasomal Degradation
Shivani Kapoor, Karthika Natarajan, Patrick R Baldwin, et al.
Cancer Cell
|
November 13, 2007
Rac guanosine triphosphatases represent integrating molecular therapeutic targets for BCR-ABL-induced myeloproliferative disease
Emily K Thomas, Jose A Cancelas, Hee-Don Chae, et al.
The Journal of Experimental Medicine
|
September 19, 2007
The PP2A inhibitor SET regulates natural killer cell IFN-gamma production
Rossana Trotta, David Ciarlariello, Jessica Dal Col, et al.
Science Signaling
|
August 1, 2013
miR-29 acts as a decoy in sarcomas to protect the tumor suppressor A20 mRNA from degradation by HuR
M Y Balkhi, Mumtaz Y Balkhi, O Hans Iwenofu, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
March 9, 2011
Mutated beta-catenin evades a microRNA-dependent regulatory loop
Angelo Veronese, Rosa Visone, Jessica Consiglio, et al.
Journal of Hematology & Oncology
|
March 19, 2013
Silvestrol exhibits significant in vivo and in vitro antileukemic activities and inhibits FLT3 and miR-155 expressions in acute myeloid leukemia
Houda Alachkar, Ramasamy Santhanam, Jason G Harb, et al.
Haematologica
|
May 11, 2019
Somatic variants in epigenetic modifiers can predict failure of response to imatinib but not to second-generation tyrosine kinase inhibitors
Georgios Nteliopoulos, Alexandra Bazeos, Simone Claudiani, et al.
Page
of 9